Salivary α-synuclein in Parkinson’s disease – a pilot study
Objective: The aim of our study was to measure total salivary α-synuclein in Parkinson´s disease (PD) patients to assess its potential as a biomarker of…Development of therapeutic substances for the disassembly of α-synuclein aggregates as disease-modifying treatment of synucleinopathies
Objective: Development of high-affinity ligands to α-synuclein (α-syn) for a therapeutic approach aiming for the disassembly of α-syn aggregates as a disease-modifying treatment of synucleinopathies.…Diagnostic and treatment burden of dystonia in Turkey: a patient journey map
Objective: To assess the burden of access to diagnosis and botulinum neurotoxin (BoNT) treatment in Turkish patients with dystonia and hemifacial spasm (PwD/HFS). Background: Diagnostic…REM sleep behaviour disorder in Parkinson’s disease: prevalence and correlation with other sleep parameters
Objective: to assess the prevalence of probable rapid eye movement (REM) sleep behavior disorder (RBD) in Parkinson’s disease (PD) patients and its correlation with other…Drivers of Health-Related Quality of Life in Parkinson’s Disease: non-motor symptoms and time spent in daily activities
Objective: The purpose of this study was to identify factors associated with health-related quality of life (HRQoL) in people with Parkinson’s Disease (PwP). Background: HRQoL…The impact on religiosity following Deep Brain Stimulation (DBS) in patients with Essential Tremor (ET) and Parkinson’s Disease (PD)
Objective: To determine the impact of DBS on religiosity. Background: Religiosity has been mapped to various brain networks1, 2, and transcranial magnetic stimulation has transiently…Dystonia Treatment With Injections Supplemented by TMS: the D-TWIST Study
Objective: To evaluate the safety, feasibility, tolerability and effects of accelerated rTMS for treatment of cervical dystonia. Background: In a subgroup of patients with cervical…Traveling through the telescope: a neuromuscular and a movement disorders reunion
Objective: We aim to raise awareness to an uncommon but possible combination of Parkinson Disease (PD) and Myasthenia Gravis (MG). Background: The co-occurrence of PD…Cerebral Topography of [11C]-Flumazenil GABAA Receptor Expression in Parkinson’s Disease Fallers and Freezers
Objective: To examine the cerebral topography of GABAA Receptor Expression in Parkinson’s Disease (PD) Fallers and Freezers. Background: Episodic mobility disturbances, like falls and freezing…Expanding the spectrum of Hereditary Spastic Paraplegia: An interesting Case .
Objective: We describe an interesting case of a young adult with a 5 year progressive history of spastic quadripareisis , cognitive decline, seizures and pseudobulbar…
- « Previous Page
- 1
- …
- 149
- 150
- 151
- 152
- 153
- …
- 186
- Next Page »